The following stocks had notable activity in their options during the past week(s): $HZNP (11/18): 1,632 FEB14 6.0 strike Calls (stock at $4.47) were purchased for 0.95 or $155,040. Buyer makes money if stock trades north of $6.95 by expiration. $NWBO (11/18): 250 APR14 7.5 strike Calls (stock at $5.71) were sold for 1.05 or […]
ASH 2013 Preview on Lymphoid Malignancies
This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking the biotech sector’s run the past 2 years. They are now within months of receiving approval for 2 indications where they could benefit patient lives […]
Quick comments on Achillion and TG Therapeutics
(with Jason Chew) In biotech, all too often are investors given news on Friday that is not so good. With many updates expected by the end of the quarter, someone was bound to have the honors of being one of those companies. Today we had quite bad news out of Achillion and an update from […]
Impressions from ASCO 2013 Days 3 and 4
Having survived ASCO 2013, we wanted to review some of the main data from Days 3 and 4. After a very long first 2 sessions, Day 3 and 4 were less data heavy, however, the outcomes from some of these had a dramatic effect for some (like CLVS, INFI, TSRO and SNTA). PD1’s belle of […]
Highlights from Day 2 at Needham
Today marked the end of the 12th Annual Needham Healthcare Conference. Below is a collection of slides from companies that we are following or have an interest in. These include Chelsea Therapeutics (CHTP), Curis (CRIS), Cytokinetics (CYTK), Intercept (ICPT), Omeros (OMER), Sangamo (SGMO), TG Therapeutics (TGTX) and several others. (See our slideshow from Day 1 […]
A look at TG Therapeutics
with Jason Chew TG Therapeutics (OTC: TGTX, formerly Manhattan Therapeutics), has caught a bit of attention recently with the rise of PI3K inhibitors. TG Therapeutics has 2 main assets: Ublituximab(TG-1101), an anti-CD20 mAb, and TGR-1202, a PI3K delta inhibitor. Both programs are currently behind competitors, but there could still exist an opportunity for both drugs. […]
Thursday at the JP Morgan Healthcare Conference
With the JP Morgan Healthcare Conference wrapped up, I wanted to highlight some notes from the Thursday session. I tried to keep them as concise as possible. We will say that we did see a lot of material that will keep up us busy for the year. You can find the webcasts to any of […]